| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Tipifarnib | FIMM | pan-cancer | AAC | -0.019 | 0.9 |
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |